Macrophage Inflammatory Protein-1 Alpha (MIP-1 alpha)/CCL3: As a Biomarker

Ishita Bhavsar, Craig S. Miller, and Mohanad Al-Sabbagh

Contents

Key Facts of MIP-1α/CCL3 ........................................................................................................... 225
Definitions of Words and Terms ................................................................................................ 226
Introduction .................................................................................................................................. 226
Background ................................................................................................................................ 227
Cells Secreting MIP-1α/CCL3 ..................................................................................................... 228
Biological Function of MIP-1α/CCL3 ......................................................................................... 229
  Inflammation ............................................................................................................................... 229
  Role of MIP-1α/CCL3 in Viral Infections ................................................................................. 230
  Wound Healing ........................................................................................................................... 232
  Inhibition of Hemopoietic Stem Cell Proliferation .................................................................. 232
  Osteoclast Activation and Multiple Myeloma .......................................................................... 233
  Malignancy, Tumor Migration, and Tumor Metastasis ............................................................. 233
  T Lymphocyte Recruitment ......................................................................................................... 234
Potential Applications to Diagnosis, Risk Assessment, and Prognosis of Diseases and Conditions ................................................................................................................................. 234
  Periodontitis ............................................................................................................................... 234
  Peri-implantitis and MIP-1α/CCL3: Findings from Oral Fluids ................................................ 235
  Periodontitis, MM, and MIP-1α/CCL3: Findings from Serum and Bone Marrow ................ 239
  Sarcoidosis and MIP-1α/CCL3 .................................................................................................... 241
  Papillon-Lefèvre Syndrome and MIP-1α/CCL3 ....................................................................... 241
  Rheumatoid Arthritis and MIP-1α/CCL3 .................................................................................. 242

I. Bhavsar • M. Al-Sabbagh (✉)
Department of Oral Health Practice, Division of Periodontology, University of Kentucky College of Dentistry, Lexington, KY, USA
e-mail: isbh222@l.uky.edu; ishita.bhavsar@uky.edu; malsa2@email.uky.edu

C.S. Miller
Department of Oral Health Practice, Division of Oral Diagnosis, Oral Medicine, Oral Radiology, University of Kentucky College of Dentistry, Lexington, KY, USA
e-mail: cmiller@uky.edu

© Springer Science+Business Media Dordrecht 2015
V.R. Preedy, V.B. Patel (eds.), General Methods in Biomarker Research and their Applications, Biomarkers in Disease: Methods, Discoveries and Applications, DOI 10.1007/978-94-007-7696-8_27
Abstract

Macrophage inflammatory protein-1 alpha (MIP-1α/CCL3) is a chemotactic chemokine secreted by macrophages. It performs various biological functions, such as recruiting inflammatory cells, wound healing, inhibition of stem cells, and maintaining effector immune response. It activates bone resorption cells and directly induces bone destruction. Cells that secrete MIP-1α/CCL3 are increased at sites of inflammation and bone resorption. MIP-1α/CCL3 plays an important role in the pathogenesis of various inflammatory diseases and conditions that exhibit bone resorption, such as periodontitis, multiple myeloma, Sjögren syndrome, and rheumatoid arthritis. Biological fluids from patients with these diseases exhibit elevated levels of MIP-1α/CCL3. This finding indicates that MIP-1α/CCL3 protein may have diagnostic potential for the detection of several inflammatory diseases and conditions. This chapter discusses the biological functions of MIP-1α/CCL3; describes several diseases associated with MIP-1α/CCL3, particularly periodontitis; and delineates the potential application of MIP-1α/CCL3 as a biomarker.

List of Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| Aa           | Aggregatibacter actinomycetemcomitans |
| ARDS         | Acute Respiratory Distress Syndrome |
| BALF         | Bronchoalveolar Lavage Fluid |
| CCR1         | Chemokine (C-C motif) Receptor 1 |
| CCR5         | Chemokine (C-C motif) Receptor 5 |
| CFU-A        | Colony-Forming Unit-Adipocyte |
| CFU-S        | Colony-Forming Unit-Spleen |
| CX3CR1       | CX3C Chemokine Receptor 1 |
| CXCR4        | CXC Chemokine Receptor 4 |
| GCF          | Gingival Crevicular Fluid |
| HIV          | Human Immunodeficiency Virus |
| HLA          | Human Leukocyte Antigen |
| ICAM-1       | Intracellular Adhesion Molecule |
| Ig           | Immunoglobulin |
| IL-1         | Interleukin-1 |
| IL-1β        | Interleukin-1 Beta |
| IL-6         | Interleukin-6 |
| IP-10/CXCL10 | Interferon-Gamma-Inducible Protein-10/Chemokine (CXC) Ligand 10 |
Key Facts of MIP-1α/CCL3

- MIP-1α/CCL3 is a type of chemotactic cytokine.
- MIP-1α/CCL3 belongs to the CC subfamily of chemokines.
- MIP-1α/CCL3 was first discovered by Stephen D. Wolpe in 1988.
- MIP-1α/CCL3 is a multifunction peptide that is secreted by a variety of hematopoietic and non-hematopoietic cells upon stimulation.
- MIP-1α/CCL3-expressing cells are usually found in areas of inflammation and bone resorption.
• MIP-1α/CCL3 recruits macrophages, lymphocytes, and eosinophils via the CCR1 or CCR5 receptor.
• MIP-1α/CCL3 preferentially attracts activated CD8+ T cells.
• MIP-1α/CCL3 exerts strong HIV-suppressive activity.
• MIP-1α/CCL3 plays an important role in the bone remodeling process by inducing osteoclastogenesis.
• MIP-1α/CCL3 is associated with periodontitis and multiple myeloma because of MIP-1α/CCL3’s biological functions of recruiting inflammatory cells and osteoclastogenesis activity.
• Increased concentrations of MIP-1α/CCL3 can be detected in biological fluids of persons suffering from inflammatory and osteoclastogenic diseases.

**Definitions of Words and Terms**

**Chemokine**  Chemokines are type of cytokines that play an important role in recruiting various cells.

**Biomarker**  A protein that can be detected in tissue or bodily fluids and that helps differentiate a disease state from a normal biological state.

**Bone Remodeling**  The process of bone resorption and bone formation.

**Sequence Homology**  Identical gene sequences.

**Tumor Metastasis**  Migration of tumor cells from the original site to a distant site (other tissue).

**Transcriptional Factors**  Proteins that help regulate gene expression (increase or decrease).

**Introduction**

The mediators responsible for recruitment, activation, and migration of immune and inflammatory cells to the site of inflammation have been studied for years. Many of these mediators are cytokines and chemokines. Cytokines belong to a group of signaling proteins that are secreted by various cells after cellular activation (Foster 2001). Growth factors, inflammatory cytokines, and chemokines are types of cytokines. Chemokines play an important role in recruiting inflammatory and immune cells to the site of infection or inflammation. They are also known as chemoattractant cytokines (Foster 2001). The typical structure of a chemokine consists of a configuration of four cysteine residues. Depending on the presence or absence of amino acid between the first two cysteine residues, chemokines are classified into two main subfamilies, CXC (alpha) and CC (beta), with the X denoting one amino acid that
The configuration of chemokines in the CC subfamily consists of two adjacent cysteines (Fernandez and Lolis 2002). Chemokines are associated with various biological functions such as homeostasis, leukocyte recruitment, wound healing, tumor metastasis, angiogenesis, and activation of the innate and adaptive immune responses (Murphy et al. 2000; Rossi and Zlotnik 2000; Fernandez and Lolis 2002). The biological functions of chemokines occur after activating specific G protein-coupled protein receptors found on the surface of a variety of cells including monocytes/macrophages, neutrophils, basophils, eosinophils, dendritic cells, lymphocytes, and platelets (Menten et al. 2002b). Upon activation, chemokines induce migration and accumulation of inflammatory cells at the source of chemokine production. It is interesting to note that chemokines can bind to more than one chemokine receptor (Fig. 2). For example, chemokine macrophage inflammatory protein-1 alpha (MIP-1α/CCL3), a chemoattractant cytokine associated with the recruitment of leukocytes in response to tissue injury or inflammation, can bind to chemokine receptors CCR1 and CCR5 (Maurer and von Stebut 2004). Owing to these dual receptors, multiple cells can be recruited by this protein.

This chapter focuses on the chemokine MIP-1α/CCL3, its biological functions, its association with several inflammatory diseases, and its potential use as a biomarker for the diagnostic assessment of various diseases, particularly periodontal disease.

**Background**

Macrophage inflammatory protein (MIP)-1α/CCL3 is an inflammatory chemokine produced by cells during infection or inflammation. It belongs to the CC chemokine family, which displays potent chemotactic properties. The MIP-1 protein was first...
identified by Stephen D. Wolpe in 1988. His research group reported the appearance of a new heparin-binding protein from the murine macrophage cell line in response to endotoxin stimulation. This protein was called macrophage inflammatory protein (MIP) because of its biological function of inducing an inflammatory response characterized by neutrophil infiltration (Wolpe et al. 1988). The initial report of the separation of MIP-1 on SDS-PAGE gel was described by Sherry et al. (1988). Their findings suggested that the MIP-1 protein was composed of two peptides. Partial sequencing revealed two proteins: MIP-1α and MIP-1β. Although these proteins exhibited slight variation in the sequence of amino acid residue at their NH2 terminals, they share approximately 56.7% sequence homology (Sherry et al. 1988). The genomic nucleotide sequence of murine MIP1α is highly homologous to human counterparts LD78alpha/GOS19-1/SCYA3 (Widmer et al. 1991). Many researchers have independently isolated human and murine MIP-1α and MIP-1β in their laboratories. For this reason, MIP-1α has more than one name in published reports. However, with the introduction of the new nomenclature, human MIP-1α is currently called chemokine (C-C motif) ligand 3 (CCL3), and MIP-1β is called chemokine (C-C motif) ligand 4 (CCL4) (Zlotnik and Yoshie 2000).

MIP-1α/CCL3 is synthetized as a precursor protein with 92 amino acids. The premature protein splits at several sites, resulting in the formation of biologically active mature protein. Chemokines exhibit a high affinity toward proteoglycans. An increased tendency of MIP-1α/CCL3 to bind with heparin (a common proteoglycan) has been demonstrated experimentally by Wolpe et al. (1988), and this binding can enhance their activity (Ali et al. 2000).

**Cells Secreting MIP-1α/CCL3**

Most mature hematopoietic cells can induce the synthesis of MIP-1α/CCL3 and MIP-1β/CCL4. Monocytes, T lymphocytes, B lymphocytes, neutrophils, dendritic cells, and natural killer cells are known to secrete MIP-1α/CCL3 (Fig. 3).
Under normal conditions, synthesis of MIP-1α/CCL3 occurs at very low levels. However, upon stimulation of receptive cells with endotoxins such as lipopolysaccharide (LPS) (Suzuki et al. 2000), virus proteins (Melchjorsen et al. 2003), or pro-inflammatory cytokines (IL-1β) (Standiford et al. 1993a), cellular signaling events are activated, and this activation induces increased production of MIP-1α/CCL3. MIP-1α levels are regulated by certain transcriptional factors. MIP-1 alpha nuclear protein (MNP) is one such transcriptional factor that induces the transcription of the MIP-1α/CCL3 gene (Ritter et al. 1995). On the other hand, prostaglandin E2 (PGE2) has been shown to inhibit the expression of MIP-1α/CCL3 from cells (dendritic cells) previously exposed to LPS (Jing et al. 2003). Non-hematopoietic cells such as osteoblasts (Kukita et al. 1997) and epithelial cells (Ryu et al. 2007) can secrete MIP-1α/CCL3 upon stimulation. MIP-1α/CCL3 is found to be one of the chemokines copiously expressed in inflamed gingival tissue and by oral epithelial keratinocytes (Gemmell et al. 2001; Kabashima et al. 2002; Ryu et al. 2007).

**Biological Function of MIP-1α/CCL3**

The biological function of MIP-1α/CCL3 are broadly illustrated in Fig. 4 and discussed below.

**Inflammation**

The inflammatory process consists of sequential cellular events that are associated with the expression of several mediators (cytokines and chemokines, including MIP-1α/CCL3) that induce the recruitment of leukocytes to the site of
inflammation (Fig. 5). After injury, vascular endothelial cells are activated (Fig. 5, step 1). The interaction between activated endothelial cells and leukocytes migrating in the circulatory system into the site of inflammation depends on cytokine production and endothelial adhesion molecules (Luscinskas et al. 1991). Unrestricted production of cytokines and chemokines can lead to tissue destruction (Fig. 5, step 3). Activated adhesion molecules help to retain leukocytes and transmigrate them into the inflamed tissues after injury (Fig. 5, step 4). It has been reported that intracellular adhesion molecules (ICAM-1) play an important role in the interaction between monocytes and endothelial cells to produce MIP-1α/CCL3 (Lukacs et al. 1994). In vitro studies have shown a strong inflammatory reaction characterized by neutrophil accumulation after subcutaneous injection of MIP-1α/CCL3 into mice footpads (Wolpe et al. 1988). Thus, MIP-1α/CCL3 is suggested to play an important role in the inflammatory process by promoting the recruitment of leukocytes (PMNs, macrophages, and lymphocytes) to the site of inflammation.

**Role of MIP-1α/CCL3 in Viral Infections**

MIP-1α/CCL3 is important for inducing the inflammatory response against viruses. For example, upon exposure of lung tissue to respiratory syncytial virus (RSV), a strong inflammation response is induced by MIP-1α/CCL3. MIP-1α/CCL3 induces recruitment and migration of eosinophils and basophils. Eosinophil
degranulation results in severe tissue damage and is suggested to contribute to the pathological process triggered by viral infections (Garofalo et al. 1992). MIP-1α/CCL3 is the most abundantly produced chemokine in mice infected with RSV, and respiratory epithelial cells and adjacent endothelial cells have been shown to be the major source of MIP-1α/CCL3. Furthermore, transgenic mice lacking the MIP-1α/CCL3 gene showed a marked decreased inflammatory response when infected with RSV (Haeberle et al. 2001). An increased level of MIP-1α/CCL3 has been detected in bronchoalveolar lavage fluid (BALF) from patients with different lung diseases such as allergen-mediated asthma (Holgate et al. 1997), acute respiratory distress syndrome (ARDS) (Goodman et al. 1996), and pulmonary fibrosis (Ziegenhagen et al. 1998). Genetically altered MIP-1α/CCL3 null mice infected with Coxsackie virus fail to develop myocarditis, and when inoculated with influenza virus, the degree of pulmonary inflammation was reduced (Cook 1996). These findings suggest that MIP-1α/CCL3 plays a significant role in promoting inflammation in response to different viral infections.

**Fig. 5 Role of MIP-1α/CCL3 in inflammation and wound healing.** Schematic representation of tissue injury followed by (1) activation of endothelial cell. (2) Numerous cytokines and chemokines are released in this process. (3) Unrestricted production of cytokines and chemokines causes tissue destruction. (4) Endothelial cell adhesion molecules produce MIP-1α/CCL3, and they recruit and retain polymorphonuclear (PMN) cells into the area of injury. (5) MIP-1α/CCL3 promotes the recruitment of macrophages and lymphocytes to the site of bacterial infection. (6) Macrophages induce phagocytosis to eliminate the bacteria and to produce growth factors that can induce wound healing. (7) Macrophages secrete various growth factors that help promote wound healing.
The transmission and progression of human immunodeficiency virus (HIV) infection is greatly controlled by chemokines and chemokine receptors. While CD4+ T lymphocytes are the primary target cells, chemokine receptors CCR5 and CXCR4 act as primary coreceptors for entry of the virus (Alfano and Poli 2005). Because MIP-1α/CCL3 binds to the chemokine receptor CCR5, it can play an important role in the etiopathogenesis of HIV infection. Some CD4+ T cells secrete HIV-suppressive factors; hence, they are not preferentially infected with HIV (Abdelwahab et al. 2003). Apart from T lymphocytes, macrophages are well-known target cells that are infected with HIV. Macrophages infected with HIV exhibit increased levels of MIP-1α/CCL3 expression, and this expression correlates with viral replication (Canque et al. 1996). Various chemokines such as regulated on activation normal T cell expressed and secreted (RANTES/CCL5), MIP-1α/CCL3, and MIP-1β/CCL4 demonstrate HIV-suppressive activity (Cocchi et al. 1995). Furthermore, experimental studies have shown antibodies against RANTES/CCL5, MIP-1α/CCL3, and MIP-1β/CCL4 can entirely block HIV-suppressive activity (Cocchi et al. 1995). These findings suggest that chemokines have a potential role in the prevention and treatment of HIV infection.

Wound Healing

At the site of injury, macrophages perform multifunctional roles to promote wound healing. They secrete various growth factors that encourage the proliferation of cells such as fibroblasts, endothelial cells, and keratinocytes. They also produce proteins that promote extracellular matrix remodeling (collagenase) and proteases. Macrophages can produce several enzymes that degrade infectious agents and induce phagocytosis (Fig. 5, step 6). Delayed wound healing and decreased phagocytic activities are found when the numbers of macrophages and monocytes are reduced (Leibovich and Ross 1975). Mediators such as MIP-1α/CCL3 may help promote wound healing activity by recruiting macrophages to the site of tissue injury. An in vitro study by DiPietro et al. reported an increase in MIP-1α/CCL3 mRNA expression and protein levels after excisional wound injury. Furthermore, they also reported that neutralization of MIP-1α/CCL3 by anti-MIP-1α antiserum decreases collagen synthesis activity, angiogenic activity, and the number of infiltrating macrophages (DiPietro et al. 1998). These findings reflect the important role of MIP-1α/CCL3 in mediating macrophage migration into wounds to mediate tissue repair.

Inhibition of Hemopoietic Stem Cell Proliferation

MIP-1α/CCL3 is implicated in the inhibition of hematopoietic stem cell proliferation. This function was not revealed until a molecule derived from macrophage (J774.2 cell culture) designated as a stem cell inhibitor (SCI) was detected by Graham et al. It was shown that SCI inhibits the proliferation of both primitive cells (CFU-A assay) and hematopoietic stem cells (CFU-S assay). Further studies
showed that SCI is identical to MIP-1α/CCL3, as demonstrated by its amino acid sequence (Graham et al. 1990). Furthermore, MIP-1α/CCL3 may play a pivotal role in protecting the hematopoietic stem cell from negative effects triggered by cytotoxic drugs during cancer treatment.

Osteoclast Activation and Multiple Myeloma

MIP-1α/CCL3 promotes the orientation and migration of osteoclasts (Fuller et al. 1995). It stimulates the process of osteoclastogenesis by directly activating osteoclast cells (Kukita et al. 1992; Watanabe et al. 2004). Increased MIP-1α/CCL3 mRNA expression has been detected in human bone marrow myelocytes and human bone tissues (Kukita et al. 1997). Moreover, CCR1, CCR3, and CX3CR1 are some of the chemokine receptors expressed by osteoclast cells (Lean et al. 2002). It is suggested that MIP-1α/CCL3 plays a key role in the bone remodeling process because it binds with the CCR1 receptor, which is predominantly expressed by osteoclasts.

Multiple myeloma (MM) is characterized by the accumulation of malignant plasma cells in the bone marrow and is associated with increased osteoclast activity. Consistent with the role of MIP-1α/CCL3, the expression of MIP-1α/CCL3 mRNA is higher in bone marrow samples from patients with MM than healthy control subjects (Choi et al. 2000), and levels of MIP-1α/CCL3 from isolated bone marrow plasma of patients with active MM are increased compared with bone marrow plasma from patients with stable disease (Choi et al. 2000). MIP-1α/CCL3 binds to CCR1 or CCR5 to induce osteoclast formation, and neutralizing antibodies of CCR1 and CCR5 inhibit the osteoclast-induced bone resorption activity of MIP-1α/CCL3 (Oba et al. 2005). A strong positive correlation exists between bone resorption markers such as urine deoxypyridinoline (UDP), serum bone-specific alkaline phosphatase (S-BALP), and serum MIP-1 levels (MIP-1α/CCL3 and MIP-1β/CCL4) in patients with multiple lytic bone lesions (Hashimoto et al. 2004). Also, serum MIP-1α/CCL3 levels correlate with the severity and prognosis of MM (Terpos et al. 2003, 2005). Therefore, it can be concluded that bone destruction in MM is a process highly associated with MIP-1α/CCL3. On the other hand, IL-1β, a potent osteoclast-activating factor, has been implicated in the etiopathogenesis of MM. However, MM patients have shown either low to no detectable levels of IL-1β protein (Choi et al. 2000). Thus, it is suggested that MIP-1α/CCL3 is more potent than IL-1β in inducing bone resorption in MM patients. Since the concentrations of the mediators causing bone destruction are elevated, evaluating their levels can serve as a diagnostic tool for the detection of disease activity.

Malignancy, Tumor Migration, and Tumor Metastasis

MIP-1α/CCL3 has been recently implicated in the regulation of tumor metastasis. Oral squamous cell carcinoma (OSCC) patients with metastatic lymph nodes have
increased mRNA expression of MIP-1α/CCL3 in comparison with same patients with non-metastatic lymph nodes, thereby suggesting a possible role of MIP-1α/CCL3 in tumor migration (Silva et al. 2007). MIP-1α/CCL3 is also produced by stimulated leukocytic cell lines or lymphoblasts from pediatric patients with acute lymphoblastic leukemia or acute myeloid leukemia (Struyf et al. 2003). In a study involving a microchemotaxis chamber, MCF-7 breast cancer cell line responded to MIP-1α/CCL3 and MIP-1β/CCL4 suggesting their potential role in the migration of breast cancer cells (Youngs et al. 1997). Wu et al. reported that CCL3-CCR5 axis may play an important role in enhancing various tumor cell functions including tumor metastasis (Wu et al. 2008). They found increased expression of the CCR5 receptor and not the CCR1 receptor in mice injected with renal cell carcinoma, a cancer known to metastasize to the bone. Their reports suggest that CCL3-CCR5 axis contributes to neovascularization by enhancing MMP-9 expression which can help degrade extracellular matrix. Furthermore, the CCL3-CCR5 axis may help in tumor progression by increasing HGF-expressing fibroblasts (angiogenic factor). The concept of tumor migration is based on the ability of chemokines to attract tumor cells to secondary sites. Thus, the quantity of chemokines produced by lymphoma or leukemia cells and the types of chemokines present at distant sites of metastasis may determine the migration of tumor cells (Menten et al. 2002a).

**T Lymphocyte Recruitment**

MIP-1α/CCL3 acts as a potent chemoattractant for T lymphocytes and therefore plays an important role in recruiting T cells during the cell-mediated immune response (Taub et al. 1993; Cook et al. 1999). The two main subsets of T lymphocytes are CD4 (helper T cells) and CD8 (cytotoxic T cells). These cells are known to produce generous amount of cytokines and are broadly categorized as Th-1-type cytokines and Th-2-type cytokines. Th-1 cytokines are potent pro-inflammatory mediators and are responsible for maintaining autoimmune responses. However, a large quantity of these pro-inflammatory cytokines can induce unobstructed tissue damage. Thus, there is a need to counterbalance the mediators that promote unrestricted tissue destruction. Th-2-type cytokines induce an anti-inflammatory response, thereby counteracting the functions of Th-1 cytokines. In general, MIP-1α/CCL3 and MIP-1β/CCL4 play a key role in determining the responses of lymphocytes. For example, MIP-1β/CCL4 selectively attracts activated CD4+ T cells (helper), and MIP-1α/CCL3 preferentially attracts activated CD8+ T cells (cytotoxic) (Taub et al. 1993).

**Potential Applications to Diagnosis, Risk Assessment, and Prognosis of Diseases and Conditions**

MIP-1α/CCL3 is associated with the activation and migration of leukocytes, and it can induce osteoclastogenesis by activating osteoclasts. As a result, MIP-1α/CCL3 has been implicated in the pathogenesis of various inflammatory diseases and
conditions such as multiple myeloma (MM), aggressive periodontitis, sarcoidosis, Papillon-Lefèvre syndrome, rheumatoid arthritis (RA), Sjögren syndrome (SS), and cardiovascular diseases.

**Periodontitis**

The periodontium includes the gingiva and the attachment apparatus surrounding each erupted tooth. The gingiva is comprised of keratinized oral squamous epithelium and the underlying connective tissue, whereas the attachment apparatus consists of the periodontal ligament (connective tissue), cementum, and the supporting alveolar bone. Their function is to attach the tooth to the alveolar bone.

Periodontitis is a chronic disease that results from the interaction between oral bacteria and the host inflammatory response. It is reported to affect nearly 47% of adults in the United States (Eke et al. 2012). Poor oral hygiene methods contribute to the accumulation of bacterial plaque formation at the interface between the tooth and the gingiva, which when chronically present causes gingivitis, a reversible inflammation of the gum tissue (i.e., gingiva). If bacterial plaque is removed daily through effective oral hygiene measures, health is quickly restored.

Periodontitis is a more serious condition than gingivitis and is characterized by the destruction of the connective tissue attachment and bone surrounding teeth. Unlike gingivitis, periodontitis requires more time and gram-negative bacteria in subgingival sites for its development. The presence of periodontal pathogens is sufficient to cause but will not predictably cause disease in all infected patients. Differential susceptibility to the bacterial by-products elicits host responses that are contributory (Seymour 1991). Although tooth-associated bacterial biofilm is the precipitating cause of periodontitis, many risk factors predispose a person to these diseases. These factors include genetic influences (IL-1β polymorphism), aging, diabetes, stress, and smoking.

**MIP-1α/CCL3 Is Upregulated in Inflamed Periodontal Tissue**

Periodontal pathogens have a unique advantage in that the dentogingival interface is an ideal substrate upon which a biofilm can be formed. The tooth penetrates the integument and is the only interface in the body where a calcified structure is in contact with the external environment and is subjected to colonization by bacteria. This tooth-associated biofilm confers a degree of protection and allows some degree of metabolic cooperation between the members of the community. Microbes are held in contiguity with the delicate epithelium that lines the gingival sulcus (a potential space between the tooth and gum). If allowed to remain in situ, the increasing anaerobic and gram-negative flora will elicit an inflammatory host response. Influx of polymorphonuclear (PMN) cells and macrophages takes place after activation of the immune reaction (Fig. 6). The exposure of the bacterial lipopolysaccharide (LPS) induces the initiation of various inflammatory cells to stimulate the expression of inflammatory cytokines such as interleukin-1 (IL-1), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) in the gingival
connective tissue. Chemokines are upregulated during the course of periodontal disease as a result of the interaction between the bacterial proteins and cellular surface receptors. Experiments have shown that MIP-1α/CCL3 expression is induced by polymorphonuclear (PMN) cells and gingival epithelial cells and not by gingival fibroblasts and human MG63 osteosarcoma cells (osteoblastic cells) when subjected to bacterial lipopolysaccharide (LPS) and interleukin (IL-1β) (Ryu et al. 2007). Epithelial keratinocytes in the oral cavity can produce various chemokines such as MCP-1/CCL2, RANTES/CCL5, MIP-1α/CCL3, and interferon-γ-inducible protein-10 (IP-10/CXCL10) (Gemmell et al. 2001). An immunohistochemistry study showed that the number of cells secreting MIP-1α/CCL3 and chemokine receptor CCR5 and CXCR3 is higher in inflamed gingival tissue than in normal healthy gingival tissue (Kabashima et al. 2002). Examination of gingival tissue biopsy samples from patients with various degrees of inflammation

Fig. 6 Role of MIP-1α/CCL3 in periodontal disease. Schematic representation of tooth surface and accumulation of dental plaque. Advanced periodontal lesions are associated with an acute inflammation reaction characterized by PMN, macrophages, and plasma cells. Increased production of cytokines and chemokines takes place in response to bacterial LPS. MIP-1α/CCL3 binds to the cells presenting its receptors and induces recruitment of macrophages to induce inflammatory and immune response in the periodontal connective tissue. MIP-1α/CCL3 also activates osteoclasts and promotes bone destruction. The numbers of B lymphocytes and Th1 cells are increased with the progression of the advanced periodontal lesion
(gingivitis and periodontitis) showed that cells from the periodontitis samples contained more MIP-1α/CCL3 than MCP-1/CCL2. Moreover, MIP-1α/CCL3 exhibited higher levels with increase in inflammation (Gemmell et al. 2001). MIP-1α/CCL3 plays a significant role in recruiting inflammatory cells that are associated with later stages of inflammation. A correlation has been reported between MIP-1α/CCL3-positive cells and an increased proportion of CD8+ T cells (cytotoxic cells) and B cells in association with increased inflammation (Gemmell et al. 2001). Correspondingly, microchemotaxis experiments have shown that MIP-1α/CCL3 has an increased tendency to attract cytotoxic T cells and B cells (Schall et al. 1993). MIP-1α/CCL3 functions by recruiting inflammatory cells to the inflamed tissue, upregulating the expression of MIP-1α/CCL3 by gingival epithelial cells to promote an acute inflammation response, and recruiting B lymphocytes in the later stages of periodontal disease. On the other hand, relative amounts of RANTES/CCL5 and IP-10/CXCL10 (specific for activated T cell) from the gingival tissues of periodontitis and gingivitis samples remained stable or reduced suggesting lack of recruitments of T-cell subsets by these chemokines. These findings indicate that MIP-1α/CCL3 plays a crucial role in recruiting leukocytes at early and later stages of periodontitis (Gemmell et al. 2001).

Previous reports have suggested that inflammatory mediators can temporarily alter the gene expression of a subset of cells. Interestingly, fibroblasts from gingival tissue express higher levels of chemokine (MIP-1α/CCL3) and cytokine (IL-6) than periodontal ligament (PDL) fibroblasts when they are subjected to LPS stimulation (Morandini et al. 2010). Thus, the differential response between gingival and PDL fibroblasts appears due to different surface receptors that bind to chemokines.

**Role of MIP-1α/CCL3 in Aggressive Periodontitis**

Aggressive periodontitis is a specific type of periodontitis that is characterized by a genetic component and rapid attachment loss and severe bone destruction. It predominantly affects children and usually involves molars and incisors. Patients often exhibit levels of bacterial plaque that are inconsistent with the amount of periodontal tissue destruction. An increased incidence of Aggregatibacter actinomycetemcomitans (Aa), a gram-negative bacteria, is a predominant feature of this disease. The local host inflammatory response is characterized by intense infiltration of PMNs, macrophages, and lymphocytes, predominantly plasma cells (about 70%) (Liljenberg and Lindhe 1980). Activated cells produce unrestricted expression of cytokines and chemokines that can further stimulate cells to produce prostaglandin E2 and tissue-degrading enzymes (Masada et al. 1990; Offenbacher et al. 1993; Okada and Murakami 1998).

MIP-1α/CCL3 has been suggested to play an important role in aggressive periodontitis by inducing the activation of osteoclasts and mediating Th-1 cytokines that promote tissue destruction (Fig. 6). MIP-1α/CCL3 can also induce osteoclast formation and stimulate osteoclastogenesis (Kukita et al. 1992; Kukita et al. 1997). MIP-1α/CCL3 elicits bone resorption primarily through its receptor CCR1, which is predominantly expressed by osteoclast cells. As a result, increased level of MIP-1α/CCL3 is one of the diagnostic features of this disease. Fine et al. performed
a longitudinal study to evaluate salivary levels of MIP-1α/CCL3 from periodontally healthy Aa⁺ and Aa⁻ subjects. Three subject groups were studied: seven subjects who developed localized aggressive periodontitis (LAgP) with clinical signs of bone loss, seven healthy subjects with no bone loss (Aa⁺), and seven healthy subjects with no bone loss (Aa⁻). Fine et al. found significantly higher levels (about 50 fold) of MIP-1α/CCL3 from subjects in the LAgP Aa⁺ group than the healthy control groups. Furthermore, levels of MIP-1α/CCL3 were found to be higher 6–9 months before the detection of bone loss. Although the number of study subjects was small, this study demonstrates the potential role of MIP-1α/CCL3 in promoting macrophage recruitment and osteoclast activation. The fact that MIP-1α/CCL3 levels were higher before the detection of bone loss suggests that this protein may play a role as a biomarker for detecting patients at risk of bone loss during the course of periodontitis.

MIP-1α/CCL3 RNA and its receptor CCR5 have also been detected at higher levels in gingival biopsy samples from patients with aggressive periodontitis than in samples from patients with chronic periodontitis (Garlet et al. 2003). Consistent with these results was the finding that the chemokine receptor CCR5 is preferentially expressed on Th1 cells rather than on Th2 cells (Loetscher et al. 1998). Thus, the expression of MIP-1α/CCL3 and its receptor CCR5 in aggressive periodontitis suggests an inclination toward the production of the Th1 cell response. One study showed that a higher level of IFN-γ (Th-1-type cytokine) is found in aggressive periodontitis, a finding suggesting the possibility of differential patterns of cytokine expression in periodontal tissue (Garlet et al. 2003). Thus, depending on the recruitment of lymphocyte subsets, differential cytokine expression is expected in areas of aggressive periodontitis.

**Association of MIP-1α/CCL3 with Periodontitis as It Can Be Measured in Bodily Fluids**

Visual evaluation, periodontal pocket depth, clinical attachment level, plaque index, bleeding upon probing, and demonstration of alveolar bone loss by radiographic images are some of the traditional parameters for diagnosing periodontal disease. However, these conventional diagnostic measures fail to recognize highly susceptible subjects who are at risk of future tissue breakdown. Also, a substantial amount of damage must take place before these diagnostic measures can detect disease activity. Hence, scientists are attempting to develop new diagnostics for detecting ongoing periodontal disease at an early stage. New diagnostics should be able to provide information about the extent of current disease activity as well as determine which patients are highly susceptible for future disease progression. Recently, the use of serum, saliva, and gingival crevicular fluid (GCF) in clinical research has provided insight into the pathogenesis of periodontitis and potential biomarkers that may have diagnostic utility. Currently, oral fluid biomarkers such as enzymes (collagenase), host cells (PMN), bacteria (Aa, Porphyromonas gingivalis), bacterial products (LPS), and immunoglobulin (IgA) show potential for detecting periodontal disease (Khashu et al. 2012).
**Periodontitis and MIP-1α/CCL3: Findings from Oral Fluids**

Saliva from patients with periodontal disease contains higher concentrations of MIP-1α/CCL3 than healthy controls. Similar to the findings of Fine et al. (2009), levels of MIP-1α/CCL3 were 18-fold higher in the saliva of 40 subjects with periodontitis than in 40 healthy control subjects (Al-Sabbagh et al. 2012). Salivary concentrations of MIP-1α/CCL3 also demonstrate a strong positive correlation with clinical parameters of periodontal disease. In addition to correlating with disease severity, salivary levels of MIP-1α/CCL3 have been shown to reflect response to therapy (Sexton et al. 2011). Tymkiv et al. reported that the level of MIP-1α/CCL3 is lower in subjects with periodontitis who smoke than in similar subjects who do not smoke (Tymkiw et al. 2011). This finding could be because smoking impairs the immune response (Palmer et al. 2005). Although MIP-1α/CCL3 appears to be a good salivary biomarker of periodontitis, one study reports that concentrations of MIP-1α/CCL3 in gingival crevicular fluid were not different in subjects presenting with increasing severities of periodontal diseases (i.e., gingivitis or chronic and aggressive periodontitis) (Emingil et al. 2005). Thus, this finding indicates more research is needed and could reflect the episodic nature of periodontal destruction activity (Socransky et al. 1984; Table 1).

**Peri-implantitis and MIP-1α/CCL3: Findings from Oral Fluids**

In dentistry, the concept of osseointegration is revolutionizing the success of dental implants as replacements for missing teeth. The demand for dental implants has grown considerably. However, implants can fail because of peri-implant disease. Peri-implant mucositis is the inflammation of the soft tissue surrounding the implant, whereas peri-implantitis is a irreversible inflammation surrounding an osseointegrated implant that leads to severe bone loss caused either by bacteria or by technical (mechanical trauma) complications (Lindhe and Meyle 2008) (Albrektsson and Isidor 1994). Several studies have shown that the progression of peri-implantitis results in a markedly higher rate of implant failure (Sakka et al. 2012). In as much as peri-implantitis is a major cause of implant failure, various salivary biomarkers have been investigated for the detection of peri-implantitis (Arakawa et al. 2012; Fonseca et al. 2012). Reports of cytokine and chemokine level in peri-implant crevicular fluid (PICF) provide valuable information about the health status of dental implants. To date, at least one study has shown that levels of PICF MIP-1α/CCL3 and IL-1β are significantly higher in patients with peri-implantitis than in patients with healthy implants (Petkovic et al. 2010).

**Periodontitis, MM, and MIP-1α/CCL3: Findings from Serum and Bone Marrow**

de Queiroz et al. compared the level of serum biomarkers of inflammation in 17 patients with chronic periodontitis and eight healthy control subjects. They found higher serum concentrations of MIP-1α/CCL3 in the periodontitis group
Table 1  The association of MIP-1α/CCL3 with periodontitis as measured in bodily fluids.  

| Sample | Periodontal disease | Main finding | References |
|--------|---------------------|--------------|------------|
| Serum  | G 17 CP 8 AP 15 H  | MIP-1α/CCL3 level was found to be elevated in the test group | de Queiroz et al. 2008 |
| GCF 15 | 26 26 15           | No significant difference in levels of MIP-1α/CCL3 was found between patients with gingivitis, patients with periodontitis (chronic or aggressive), and the healthy control group | Emingil et al. 2005 |
| GCF 40 | 20 smokers 20 nonsmokers 12 | MIP-1α/CCL3 levels were lower in patients with periodontitis who smoked than in those who did not smoke | Tymkiw et al. 2011 |
| Saliva  | 7 Aa+ group who developed bone loss 7 Aa+, healthy group subjects with no bone loss 7 Aa−, healthy group | MIP-1α/CCL3 levels were 50-fold higher in subjects with LAgP Aa+ group The levels of MIP-1α/CCL3 were found to be increased 6–9 months before the detection of bone loss | Fine et al. 2009 |
| Saliva  | 40 40 | MIP-1α/CCL3 levels were 18-fold higher in the periodontitis group | Al-Sabbagh et al. 2012 |
| Saliva  | 33 (OHI) 35 (SRP+ OHI) | A significant reduction in MIP-1α/CCL3 levels was found in patients who responded to periodontal therapy (SRP + OHI) compared to those who did not | Sexton et al. 2011 |
than the healthy control group, but not statistically higher levels (de Queiroz et al. 2008). In contrast to serum studies, freshly isolated bone marrow plasma from patients with active MM exhibited higher concentrations of MIP-1α/CCL3 than plasma from patients with stable disease (Choi et al. 2000). Likewise, MM patients with more than three lytic lesions exhibit higher serum MIP-1α/CCL3 concentrations than MM patients with fewer (less than 3) lytic lesions (Terpos et al. 2005) suggesting that serum MIP-1α/CCL3 levels and markers of bone resorption correlate with disease severity of MM (Terpos et al. 2003; Hashimoto et al. 2004), but less so with periodontal disease.

**Sarcoidosis and MIP-1α/CCL3**

Sarcoidosis is a chronic granulomatous disease characterized by the accumulation of T lymphocytes and macrophages; this accumulation produces inflammatory reactions in various organs. Because MIP-1α/CCL3 is a potent macrophage chemotaxin, its role in the pathogenesis of sarcoidosis is significant. Patients with sarcoidosis exhibit higher concentrations of MIP-1α/CCL3 from bronchoalveolar lavage fluid (BALF) and a 2.5-fold increase in chemotactic activity when compared to control subjects. Also, reductions in chemotaxis of approximately 22% were observed in the presence of anti-MIP-1α antibodies (Standiford et al. 1993b). These findings suggest that the plasma concentration of MIP-1α/CCL3 is related to the disease activity of sarcoidosis. Patients with active sarcoidosis, including both systemic and pulmonary involvement, showed a marked increase in plasma levels of MIP-1α/CCL3 (Hashimoto et al. 1998). However, patients with predominantly pulmonary involvement without any systemic manifestation also showed elevated concentrations of MIP-1α/CCL3. Thus, the plasma concentration of MIP-1α/CCL3 can provide valuable information about potential extrathoracic disease activity in patients with sarcoidosis and can correlate with disease activity.

**Papillon-Lefèvre Syndrome and MIP-1α/CCL3**

Papillon-Lefèvre syndrome (PLS) is a rare autosomal recessive disorder initially reported by Papillon and Lefèvre in 1924. It is characterized by early loss of both deciduous and permanent dentition and by palmar-plantar keratosis. Reports have shown that a genetic mutation of the chromosome (11q14-21) that results in complete loss of cathepsin C activity is responsible for the development of PLS (Hart et al. 1999). These patients exhibit severe periodontitis, which involves uncontrolled destruction of connective tissue and alveolar bone resorption. This occurs because of the downregulation of cathepsin C that impedes the activation of neutrophil serine proteinases such as cathepsin G, proteinase 3, and elastase (de Haar et al. 2004). Neutrophil serine proteinases are important for maintaining host immune functions. Patients with PLS demonstrate impaired proteolysis of MIP-1α/CCL3 because of the inactivity of neutrophil serine proteinases resulting
in severe periodontal destruction attributed to excessive buildup of MIP-1α/CCL3 (Ryu et al. 2005).

**Rheumatoid Arthritis and MIP-1α/CCL3**

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease that predominantly affects synovial joints. It is genetically associated with HLA antigen DR4 (Gran et al. 1983). During the progression of this disease, inflamed synovial joints are infiltrated by various inflammatory cells, such as macrophages, lymphocytes, and plasma cells. The activated cells produce pro-inflammatory cytokines such as TNF-α, which further mediates inflammatory synovitis and induces matrix metalloproteinase to promote collagen fiber destruction. Macrophages also play an important role in secreting chemokines involved in the pathogenesis of rheumatic arthritis. MIP-1α/CCL3 expression is higher in synovial fluid and serum from RA patients than in these fluids from patients with osteoarthritis (Koch et al. 1994). Increased levels of MIP-1α/CCL3 mRNA and protein also have been found in macrophages from the synovial tissue from RA patients. The higher expression can be attributed to an increase in the recruitment of macrophages and T cells into the areas of inflamed synovium by MIP-1α/CCL3. Likewise, increased expression of the chemokine receptor for MIP-1α/CCL3, CCR5, occurs in RA patients (Patel et al. 2001).

**Sjögren Syndrome and MIP-1α/CCL3**

The pathogenesis of Sjögren syndrome (SS) is unclear; it is characterized by a chronic inflammation of the salivary glands, which is driven by interferon-related dysregulation resulting in damage to the glands and impaired excretion of saliva (Lessard et al. 2013). Clinically, patients exhibit dry eyes and a dry mouth; however, other organs can be involved. Biopsy samples from salivary glands of patients with SS express higher concentrations of both MIP-1α/CCL3 and MIP-1β/CCL4 than that of RANTES/CCL5 and IL-8. In these studies, the ductal epithelial cells express higher concentrations of MIP-1β/CCL4 than MIP-1α/CCL3 (Cuello et al. 1998). It has been suggested that the main causative factor in the development of SS is either the recruitment of leukocytes into the ductal epithelium by chemokines or the secretion of various pro-inflammatory cytokines by these cells.

**Cardiovascular Diseases and MIP-1α/CCL3**

Recent studies indicate the pathogenic role of C-C chemokines in the development of several cardiovascular diseases such as atherosclerosis (Braunersreuther et al. 2007; de Jager et al. 2013), myocardial ischemia (de Jager et al. 2008), and
congestive heart failure (Aukrust et al. 1998). This is due to their biological function of activation and migration of leukocytes into areas of inflammation. Clinical studies have recently identified elevated concentrations of circulating chemotactic chemokines, thereby suggesting their potential as diagnostic markers of cardiovascular diseases. For example, serum concentrations of MCP-1/CCL2, MIP-1α/CCL3, and RANTES/CCL5 are elevated in patients with congestive heart failure (Aukrust et al. 1998). Patients with acute myocardial infarction associated with heart failure complication and severe left ventricular dysfunction also show a higher concentration of circulating MIP-1α/CCL3 in comparison with healthy control patients (Parissis et al. 2002). Furthermore, a strong correlation between myocardial infarction and MIP-1α/CCL3 has been reported suggesting its strong prognostic potential to identify high-risk patients (de Jager et al. 2008, 2012). Increasing evidence suggest that C-C chemokines (MIP-1α/CCL3) and their receptors play a significant role in the etiopathogenesis of the cardiovascular disease. Therefore, inhibition of these chemokines and their receptors could provide novel therapeutic strategies.

**Conclusion**

In conclusion, MIP-1α/CCL3 plays a key role in the activation and regulation of inflammatory and host defense responses. MIP-1α/CCL3 is crucial for the recruitment of macrophages and T lymphocytes from the circulation to sites of infection or injury; thus, it orchestrates acute and chronic inflammatory host responses. It also acts as a potent osteoclast activator and induces bone resorption. Hence, MIP-1α/CCL3 is a key protein that plays an important pathological role in the development of several inflammatory and autoimmune diseases such as multiple myeloma, rheumatoid arthritis, Sjögren syndrome, sarcoidosis, respiratory disease, cardiovascular disease, and periodontitis. Evaluating the levels of MIP-1α/CCL3 in biological fluids provides a great opportunity for diagnosing various inflammatory diseases and conditions at their early stages. Moreover, inhibitors of MIP-1α/CCL3 and its receptors could be potential therapeutic targets for the treatment of these diseases.

**Summary Points**

- MIP-1α/CCL3 is a key chemokine that plays an important role in recruiting inflammatory cells (macrophages, lymphocytes, eosinophil, and basophils) to the site of injury or inflammation.
- MIP-1α/CCL3 is expressed by several cells upon stimulation of endotoxins such as LPS, viral proteins, and pro-inflammatory cytokines.
- MIP-1α/CCL3 performs important biological functions, such as the initiation of the inflammatory response by the recruitment of macrophages, wound healing,
tumor metastasis, promoting osteoclast activation, HIV-suppressive activity, and inhibition of hematopoietic stem cells, principally by binding to their selective chemokine receptors CCR1 and CCR5.

- MIP-1α/CCL3 induces osteoclastogenesis by directly activating osteoclasts; therefore, it is suggested to be a main etiological factor in diseases such as multiple myeloma and periodontitis that are characterized by severe tissue destruction and bone destruction.

- MIP-1α/CCL3 is associated with several inflammatory diseases including Papillon-Lefèvre syndrome, peri-implantitis, sarcoidosis, Sjögren syndrome, and rheumatoid arthritis.

- Detection of increased concentrations of MIP-1α/CCL3 in bodily fluids (serum, saliva, GCR, bronchial lavage) is a promising approach for detecting disease risk, disease activity, and response to therapy regarding several inflammatory and osseous destructive diseases.

References

Abdelwahab SF, Cocchi F, Bagley KC, Kamin-Lewis R, Gallo RC, DeVico A, Lewis GK. HIV-1-suppressive factors are secreted by CD4+ T cells during primary immune responses. Proc Natl Acad Sci U S A. 2003;100(25):15006–10.

Albrektsson T, Isidor F. Consensus report of session IV. In: Lang NP, Karring T (eds). Proceedings of the First European Workshop on Periodontology. London: Quintessence, 1994;365–369.

Alfano M, Poli G. Role of cytokines and chemokines in the regulation of innate immunity and HIV infection. Mol Immunol. 2005;42(2):161–82.

Ali S, Palmer AC, Banerjee B, Fritchley SJ, Kirby JA. Examination of the function of RANTES, MIP-1alpha, and MIP-1beta following interaction with heparin-like glycosaminoglycans. J Biol Chem. 2000;275(16):11721–7.

Al-Sabbagh M, Alladah A, Lin Y, Kryscio RJ, Thomas MV, Ebersole JL, Miller CS. Bone remodeling-associated salivary biomarker MIP-1alpha distinguishes periodontal disease from health. J Periodontal Res. 2012;47(3):389–95.

Arakawa H, Uehara J, Hara ES, Sonoyama W, Kimura A, Kanyama M, Matsuka Y, Kuboki T. Matrix metalloproteinase-8 is the major potential collagenase in active peri-implantitis. J Prosthodont Res. 2012;56(4):249–55.

Aukrust P, Ueland T, Muller F, Andreassen AK, Nordoy I, Aas H, Kjekshus J, Simonsen S, Froland SS, Gullestad L. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation. 1998;97(12):1136–43.

Braunersreuther V, Mach S, Steffens S. The specific role of chemokines in atherosclerosis. Thromb Haemost. 2007;97(5):714–21.

Canque B, Rosenzwaig M, Gey A, Tartour E, Fridman WH, Gluckman JC. Macrophage inflammatory protein-1alpha is induced by human immunodeficiency virus infection of monocyte-derived macrophages. Blood. 1996;87(5):2011–9.

Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, Alsina M. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood. 2000;96(2):671–5.

Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science. 1995;270(5243):1811–5.

Cook DN. The role of MIP-1 alpha in inflammation and hematopoiesis. J Leukoc Biol. 1996;59(1):61–6.
Cook DN, Smithies O, Strieter RM, Frelinger JA, Serody JS. CD8+ T cells are a biologically relevant source of macrophage inflammatory protein-1 alpha in vivo. J Immunol. 1999;162(9):5423–8.

Cuello C, Palladinetti P, Tedla N, Di Girolamo N, Lloyd AR, McCluskey PJ, Wakefield D. Chemokine expression and leucocyte infiltration in Sjögren’s syndrome. Br J Rheumatol. 1998;37(7):779–83.

de Haar SF, Jansen DC, Schoenmaker T, De Vree H, Everts V, Beertsen W. Loss-of-function mutations in cathepsin C in two families with Papillon-Lefèvre syndrome are associated with deficiency of serine proteinases in PMNs. Hum Mutat. 2004;23(5):524.

de Jager SC, Kraaijveld AO, Grauss RW, de Jager W, Liem SS, van de Hoeven BL, Prakken BJ, Putter H, van Berkel TJ, Atsma DE, Schalij MJ, Jukema JW, Biessen EA. CCL3 (MIP-1 alpha) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events. J Mol Cell Cardiol. 2008;45(3):446–52.

de Jager SC, Bongaerts BW, Weber M, Kraaijveld AO, Rousch M, Dimmeler S, van Dieijen-Visser MP, Cleutjens KB, Nelemans PJ, van Berkel TJ, Biessen EA. Chemokines CCL3/MIP1alpha, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes. PLoS One. 2012;7(9):e45804.

de Jager SC, Bot I, Kraaijveld AO, Korporaal SJ, Bot M, van Santbrink PJ, van Berkel TJ, Kuiper J, Biessen EA. Leukocyte-specific CCL3 deficiency inhibits atherosclerotic lesion development by affecting neutrophil accumulation. Arterioscler Thromb Vasc Biol. 2013;33(3):e75–83.

de Queiroz AC, Taba Jr M, O’Connell PA, da Nobrega PB, Costa PP, Kawata VK, Trevisan GL, Novaes Jr AB, de Souza SL, Palioato DB, Grisi MF. Inflammation markers in healthy and periodontitis patients: a preliminary data screening. Braz Dent J. 2008;19(1):3–8.

DiPietro LA, Burdick M, Low QE, Kunkel SL, Strieter RM. MIP-1alpha as a critical macrophage chemoattractant in murine wound repair. J Clin Invest. 1998;101(8):1693–8.

Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91(10):914–20.

Emingil G, Atilla G, Baskesen A, Berdeli A. Gingival crevicular fluid EMAP-II, MIP-1alpha and MIP-1beta levels of patients with periodontal disease. J Clin Periodontol. 2005;32(8):880–5.

Fernandez EJ, Lolis E. Structure, function, and inhibition of chemokines. Annu Rev Pharmacol Toxicol. 2002;42:469–99.

Fine DH, Markowitz K, Furgang D, Fairlie K, Ferrandiz J, Nasri C, McKiernan M, Donnelly R, Gunsolley J. Macrophage inflammatory protein-1alpha: a salivary biomarker of bone loss in a longitudinal cohort study of children at risk for aggressive periodontal disease? J Periodontol. 2009;80(1):106–13.

Fonseca FJ, Junior MM, Lourenco EJ, de Moraes Teles D, Figueredo CM. Cytokines expression in saliva and peri-implant crevicular fluid of patients with peri-implant disease. Clin Oral Implants Res. 2012;25:e68–72.

Foster JR. The functions of cytokines and their uses in toxicology. Int J Exp Pathol. 2001;82(3):171–92.

Fuller K, Owens JM, Chambers TJ. Macrophage inflammatory protein-1 alpha and IL-8 stimulate the motility but suppress the resorption of isolated rat osteoclasts. J Immunol. 1995;154(11):6065–72.

Garlet GP, Martins Jr W, Ferreira BR, Milanezi CM, Silva JS. Patterns of chemokines and chemokine receptors expression in different forms of human periodontal disease. J Periodontal Res. 2003;38(2):210–7.

Garofalo R, Kimpen JL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr. 1992;120(1):28–32.

Gemmell E, Carter CL, Seymour GJ. Chemokines in human periodontal disease tissues. Clin Exp Immunol. 2001;125(1):134–41.
Goodman RB, Strieter RM, Martin DP, Steinberg KP, Milberg JA, Maunzer RJ, Kunkel SL, Walz A, Hudson LD, Martin TR. Inflammatory cytokines in patients with persistence of the acute respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(3 Pt 1):602–11.

Graham GI, Wright EG, Hewick R, Wolke SD, Wilkie NM, Donaldson D, Lorimore S, Pragnell IB. Identification and characterization of an inhibitor of haemopoietic stem cell proliferation. Nature. 1990;344(6265):442–4.

Gran JT, Husby G, Thorsby E. The association between rheumatoid arthritis and the HLA antigen DR4. Ann Rheum Dis. 1983;42(3):292–6.

Haeberle HA, Kuziel WA, Dieterich HJ, Casola A, Gatalica Z, Garofalo RP. Inducible expression of inflammatory chemokines in respiratory syncytial virus-infected mice: role of MIP-1alpha in lung pathology. J Virol. 2001;75(2):878–90.

Hart TC, Hart PS, Bowden DW, Michalec MD, Callison SA, Walker SJ, Zhang Y, Firatli E. Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome. J Med Genet. 1999;36(12):881–7.

Hashimoto S, Nakayama T, Gon Y, Hata N, Koura T, Maruoka S, Matsumoto K, Hayashi S, Abe Y, Horie T. Correlation of plasma monocyte chemoattractant protein-1 (MCP-1) and monocyte inflammatory protein-lalpha (MIP-lalpha) levels with disease activity and clinical course of sarcoidosis. Clin Exp Immunol. 1998;111(3):604–10.

Hashimoto T, Abe M, Oshima T, Shibata H, Ozaki S, Inoue D, Matsumoto T. Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1alpha and MIP-1beta correlates with lytic bone lesions in patients with multiple myeloma. Br J Haematol. 2004;125(1):38–41.

Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of RANTES, MIP-1 alpha, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med. 1997;156(5):1377–83.

Jing H, Vassiliou E, Ganea D. Prostaglandin E2 inhibits production of the inflammatory chemokines CCL3 and CCL4 in dendritic cells. J Leukoc Biol. 2003;74(5):868–79.

Kabashima H, Yoned M, Nagata K, Hirofuji T, Maeda K. The presence of chemokine (MCP-1, MIP-1alpha, MIP-1beta, IP-10, RANTES)-positive cells and chemokine receptor (CCR5, CXCR3)-positive cells in inflamed human gingival tissues. Cytokine. 2002;20(2):70–7.

Khashu H, Baiju CS, Bansal SR, Chhillar A. Salivary biomarkers: a periodontal overview. J Oral Health Comm Dent. 2012;6(1):28–33.

Koch AE, Kunkel SL, Harlow LA, Mazarakis DD, Haines GK, Burdick MD, Pope RM, Strieter RM. Macrophage inflammatory protein-1 alpha. A novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest. 1994;93(3):921–8.

Kukita T, Nakao J, Hamada F, Kukita A, Inai T, Kurisu K, Nomiyama H. Recombinant LD78 protein, a member of the small cytokine family, enhances osteoclast differentiation in rat bone marrow culture system. Bone Miner. 1992;19(3):215–23.

Kukita T, Nomiyama H, Ohmoto Y, Kukita A, Shuto T, Hotekebuchi T, Sugioya K, Miura R, Iijima T. Macrophage inflammatory protein-1 alpha (LD78) expressed in human bone marrow: its role in regulation of hematopoiesis and osteoclast recruitment. Lab Invest. 1997;76(3):399–406.

Lean JM, Murphy C, Fuller K, Chambers TJ. CCL9/MIP-1gamma and its receptor CCR1 are the major chemokine ligand/receptor species expressed by osteoclasts. J Cell Biochem. 2002;87(4):386–93.

Leibovich SJ, Ross R. The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol. 1975;78(1):71–100.

Lessard CJ, Li H, Adrianto I, Ice JA, Rasmussen A, Grundahl KM, Kelly JA, Dozomorov MG, Miceli-Richard C, Bowman S, Lester S, Eriksson P, Eloranta ML, Brun JG, Goransson LG, Harboe E, Guthridge JM, Kaufman KM, Kvarnstrom M, Jazebi H, Graham DS, Grandits ME, Nazmul-Hossain AN, Patel K, Adler AJ, Maier-Moore JS, Farris AD, Brennan MT, Lessard JA, Chodos J, Gopalakrishnan R, Hefner KS, Houston GD, Huang AJ, Hughes PJ, Lewis DM, Radfar L, Rohrer MD, Stone DU, Wren JD, Vye TJ, Gaffney PM, James JA, Omdal R, Wahren-Herlenius M, Illei GG, Witte T, Jonsson R, Rischmueller M, Ronnblo L, 246

I. Bhavsar et al.
Nordmark G, Ng WF, Mariette X, Anaya JM, Rhodus NL, Segal BM, Scofield RH, Montgomery CG, Harley JB, Sivils KL. Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjogren’s syndrome. Nat Genet. 2013;45:1284–92.

Liljenberg B, Lindhe J. Juvenile periodontitis. Some microbiological, histopathological and clinical characteristics. J Clin Periodontol. 1980;7(1):48–61.

Lindhe J, Meyle J. Peri-implant diseases: Consensus Report of the Sixth European Workshop on Periodontology. J Clin Periodontol. 2008;35(8 Suppl):282–5.

Loetscher P, Uguccioni M, Bordoli L, Baggioiini M, Moser B, Chizzolini C, Dayer JM. CCR5 is characteristic of Th1 lymphocytes. Nature. 1998;391(6665):344–5.

Lükacs NW, Strieter RM, Elner VM, Evanoff HL, Burdick M, Kunkel SL. Intercellular adhesion molecule-1 mediates the expression of monocyte-derived MIP-1 alpha during monocyte-endothelial cell interactions. Blood. 1994;83(5):1174–8.

Luscinskas FW, Cybulsky MI, Kiely JM, Peckins CS, Davis VM, Giimbrome Jr MA. Cytokine-activated human endothelial monolayers support enhanced neutrophil transmigration via a mechanism involving both endothelial-leukocyte adhesion molecule-1 and intercellular adhesion molecule-1. J Immunol. 1991;146(5):1617–25.

Masada MP, Persson R, Kenney JS, Lee SW, Page RC, Allison AC. Measurement of interleukin-1 alpha and -1 beta in gingival crevicular fluid: implications for the pathogenesis of periodontal disease. J Periodontal Res. 1990;25(3):156–63.

Maurer M, von Stebut E. Macrophage inflammatory protein-1. Int J Biochem Cell Biol. 2004;36(10):1882–6.

Melchjorsen J, Sorensen LN, Paludan SR. Expression and function of chemokines during viral infections: from molecular mechanisms to in vivo function. J Leukoc Biol. 2003;74(3):331–43.

Menten P, Saccani A, Dillen C, Wuys A, Struuf P, Proost P, Mantovani A, Wang JM, Van Damme J. Role of the autocrine chemokines MIP-1alpha and MIP-1beta in the metastatic behavior of murine T cell lymphoma. J Leukoc Biol. 2002;25(3):156–63.

Menten P, Wuys A, Van Damme J. Macrophage inflammatory protein-1. Cytokine Growth Factor Rev. 2002b;13(6):455–81.

Morandini AC, Sipert CR, Gasparotto TH, Gerehi SL, Passani E, Rezende ML, Sant’ana AP, Campanelli AP, Garlet GP, Santos CF. Differential production of macrophage inflammatory protein-1alpha, stromal-derived factor-1, and IL-6 by human cultured periodontal ligament and gingival fibroblasts challenged with lipopolysaccharide from P. gingivalis. J Periodontol. 2010;81(2):310–7.

Murphy PM, Baggioiini M, Charo IF, Hebert CA, Horuk R, Matsushima K, Miller LH, Oppenheim JJ, Power CA. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev. 2000;52(1):143–76.

Oba Y, Lee JW, Ehrlich LA, Chung HY, Jelinek DF, Callander NS, Horuk R, Choi SJ, Roodman GD. MIP-1alpha utilizes both CCR1 and CCR5 to induce ostecloclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol. 2005;33(3):272–8.

Offenbacher S, Heasman PA, Collins JG. Modulation of host PGE2 secretion as a determinant of periodontal disease expression. J Periodontol. 1993;64(5 Suppl):432–44.

Okada H, Murakami S. Cytokine expression in periodontal health and disease. Crit Rev Oral Biol Med. 1998;9(3):248–66.

Palmer RM, Wilson RF, Hasan AS, Scott DA. Mechanisms of action of environmental factors—tobacco smoking. J Clin Periodontol. 2000;32 Suppl 6:180–95.

Parissis JT, Adamopoulos S, Venetsanou KF, Mentzikoig DG, Karas SM, Kremastinos DT. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J Interferon Cytokine Res. 2002;22(2):223–9.

Patel DD, Zachariah JP, Whichard LP. CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. Clin Immunol. 2001;98(1):39–45.

Petkovic AB, Matic SM, Stamatoigic NV, Vojvodic DV, Todovic TM, Lazic ZR, Kozomara RJ. Proinflammatory cytokines (IL-1beta and TNF-alpha) and chemokines (IL-8 and
MIP-1alpha) as markers of peri-implant tissue condition. Int J Oral Maxillofac Surg. 2010;39(5):478–85.

Ritter LM, Bryans M, Abd o O, Sharma V, Wilkie NM. MIP1 alpha nuclear protein (MNP), a novel transcription factor expressed in hematopoietic cells that is crucial for transcription of the human MIP-1 alpha gene. Mol Cell Biol. 1995;15(6):3110–8.

Rossi D, Zlotnik A. The biology of chemokines and their receptors. Annu Rev Immunol. 2000;18:217–42.

Ryu OH, Choi SJ, Firatli E, Choi SW, Hart PS, Shen RF, Wang G, Wu WW, Hart TC. Proteolysis of macrophage inflammatory protein-1alpha isoforms LD78beta and LD78alpha by neutrophil-derived serine proteases. J Biol Chem. 2005;280(17):17415–21.

Sakka S, Baroudi K, Nassani MZ. Factors associated with early and late failure of dental implants. J Investig Clin Dent. 2012;3(4):258–61.

Schall TJ, Bacon K, Camp RD, Kaspari JW, Goeddel DV. Human macrophage inflammatory protein alpha (MIP-1 alpha) and MIP-1 beta chemokines attract distinct populations of lymphocytes. J Exp Med. 1993;177(6):1821–6.

Sexton WM, Lin Y, Kryscio RJ, Dawson 3rd DR, Ebersole JL, Miller CS. Salivary biomarkers of periodontal disease in response to treatment. J Clin Periodontol. 2011;38(5):434–41.

Seymour GJ. Importance of the host response in the periodontium. J Clin Periodontol. 1991;18(6):421–6.

Sherry B, Tekamp-Olson P, Gallegos C, Bauer D, Davatelis G, Wolpe SD, Masiarz F, Coit D, Cerami A. Resolution of the two components of macrophage inflammatory protein 1, and cloning and characterization of one of those components, macrophage inflammatory protein 1 beta. J Exp Med. 1988;168(6):2251–9.

Socrona SS, Haffajee AD, Goodson JM, Lindhe J. New concepts of destructive periodontal disease. J Clin Periodontol. 1984;11(1):21–32.

Standiford TJ, Kunkel SL, Liebler JM, Burdick MD, Gilbert AR, Strieter RM. Gene expression of macrophage inflammatory protein-1 alpha from human blood monocytes and alveolar macrophages is inhibited by interleukin-4. Am J Respir Cell Mol Biol. 1993a;9(2):192–8.

Standiford TJ, Rolfe MW, Kunkel SL, Lynch 3rd JP, Burdick MD, Gilbert AR, Orringer MB, Whyte RI, Strieter RM. Macrophage inflammatory protein-1 alpha expression in interstitial lung disease. J Immunol. 1993b;151(5):2852–63.

Suzuki T, Hashimoto S, Toyoda N, Nagai S, Yamazaki N, Dong HY, Sakai J, Yamashita T, Nukiwa T, Matsushima K. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood. 2000;96(7):2584–91.

Taub DD, Conlon K, Lloyd AR, Oppenheim JJ, Kelvin DJ. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta. Science. 1993;260(5106):355–8.

Terpos E, Politou M, Szydlo R, Goldman JM, Apperley JF, Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol. 2003;123(1):106–9.

Terpos E, Politou M, Viniou N, Rahemtulla A. Significance of macrophage inflammatory protein-1 alpha (MIP-1alpha) in multiple myeloma. Leuk Lymphoma. 2005;46(12):1699–707.
Tymkiw KD, Thunell DH, Johnson GK, Joly S, Burnell KK, Cavanaugh JE, Brogden KA, Guthmiller JM. Influence of smoking on gingival crevicular fluid cytokines in severe chronic periodontitis. J Clin Periodontol. 2011;38(3):219–28.

Watanabe T, Kukita T, Kukita A, Wada N, Toh K, Nagata K, Nomiyama H, Iijima T. Direct stimulation of osteoclastogenesis by MIP-1alpha: evidence obtained from studies using RAW264 cell clone highly responsive to RANKL. J Endocrinol. 2004;180(1):193–201.

Widmer U, Yang Z, van Deventer S, Manogue KR, Sherry B, Cerami A. Genomic structure of murine macrophage inflammatory protein-1 alpha and conservation of potential regulatory sequences with a human homolog. LD78. J Immunol. 1991;146(11):4031–40.

Wolpe SD, Davatelis G, Sherry B, Beutler B, Hesse DG, Nguyen HT, Moldawer LL, Nathan CF, Lowry SF, Cerami A. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1988;167(2):570–81.

Wu Y, Li YY, Matsushima K, Baba T, Mukaida N. CCL3-CCR5 axis regulates intratumoral accumulation of leukocytes and fibroblasts and promotes angiogenesis in murine lung metastasis process. J Immunol. 2008;181(9):6384–93.

Youngs SJ, Ali SA, Taub DD, Rees RC. Chemokines induce migrational responses in human breast carcinoma cell lines. Int J Cancer. 1997;71(2):257–66.

Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med. 1998;46(5):223–31.

Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12(2):121–7.